Romark is among the many companies working to respond to the novel coronavirus global health emergency. Romark has on-going clinical studies of its investigational new drug candidate NT-300 (nitazoxanide extended-release) for both the prevention and treatment of COVID-19 and other viral respiratory illnesses. See below for more information.
Romark completed its clinical trial of NT-300 (nitazoxanide extended-release) in the treatment of mild or moderate COVID-19.
Information about the trial is available at the following link:
Romark also has on-going Phase 3 clinical trials of NT-300 (nitazoxanide extended-release tablets) for the prevention of COVID-19 and the treatment of viral respiratory illnesses caused by rhinoviruses and other enteroviruses.
Information about the trials is available at the following links:
1) Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long Term Care Facilities
2) Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
3) Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
To get involved, email: firstname.lastname@example.org or call 877-925-4642.
NT-300 is an investigational new drug product and has not been approved by the U.S. Food and Drug Administration or other regulatory authorities for any use. The safety and efficacy of this new product has not been established.